Blog - Page 18 of 19 - Boardroom Buzz

PredictAP Secures U.S. Patent for AI-Powered Invoice Coding Technology

Tech

Staff Writer

-

March 22, 2025

PredictAP Secures U.S. Patent for AI-Powered Invoice Coding Technology

PredictAP, an AI-powered invoice coding solution for real estate accounts payable (AP), today announced it has been awarded a U.S. patent for its innovative AP automation technology. This patent protects the proprietary approach PredictAP has taken in developing its advanced prediction engine, reinforcing its position as a leader in AI-driven invoice processing.

Founded in 2020, PredictAP has revolutionized real estate accounting by streamlining invoice processing and categorization through automation. The platform leverages machine learning to analyze customers’ historical invoice data, as well as advanced training models to identify and replicate data entry with precision.

“Securing this patent is a major milestone, confirming our groundbreaking work in enhancing AP automation with true intelligence. This firmly underscores our commitment to push the boundaries of innovation and deliver a best-in-class product.”Post this

“Securing this patent is a major milestone, confirming our groundbreaking work in enhancing AP automation with true intelligence,” said David Stifter, chief executive officer and founder of PredictAP. “PredictAP isn’t just about processing invoices—it’s about understanding context, coding with accuracy and fundamentally improving accounting operations for multifamily operators. This firmly underscores our commitment to push the boundaries of innovation and deliver a best-in-class product.”

PredictAP goes beyond traditional Optical Character Recognition (OCR) technology, which extracts text but often struggles with complex invoices where key details are missing. Unlike its competitors, PredictAP’s patented approach enables a deeper understanding of invoice structures and patterns, allowing for greater accuracy and efficiency in data entry. Clients not only reduce manual workload but also save time and avoid unnecessary costs, such as late fees.

“The multifamily industry has long struggled with the inefficiencies of manual invoice processing, and previous attempts to solve the issue have fallen short,” said Russell Franks, president and co-founder of PredictAP. “This patent recognizes PredictAP’s unique ability to go beyond basic OCR, bringing unmatched accuracy and efficiency to accounting teams. With our clients experiencing transformative results, I’m proud to say this is just the beginning of what we aim to achieve.”

PredictAP’s rapidly growing client base consists of over 70 real estate organizations, including industry leaders like Bridge Investment Group, Garden Homes and Related Group. Designed for seamless integration with top AP workflow automation solutions, PredictAP enhances efficiency and drives significant cost savings for multifamily operators.

About PredictAP

PredictAP is the leading AI-powered invoice coding solution designed specifically for real estate. Unlike OCR and indexing services, PredictAP provides fully coded invoices, ready to flow through existing AP automation workflows. When paired with industry-leading AP automation solutions, such as Yardi Payscan and Nexus Systems, PredictAP delivers massive cost savings and productivity growth.

Founded in 2020 by a team of real estate, accounting tech, and artificial intelligence industry alumni, PredictAP is based in Boston, Massachusetts. Visit www.predictap.com to learn more.

Generative AI Medical Writing Tool for the Pharmaceutical and Biotechnology Industries From TrialAssure Gets a Major Upgrade to Make Scientific Document Creation Easier

Staff Writer

-

March 22, 2025

0

Generative AI Medical Writing Tool for the Pharmaceutical and Biotechnology Industries From TrialAssure Gets a Major Upgrade to Make Scientific Document Creation Easier

TrialAssure®, a global leader in AI-enabled, human-driven solutions for the pharmaceutical industry and beyond, today announced a groundbreaking addition to its TrialAssure LINK® AI content creation and medical writing tool. The new Microsoft Word AI Assistant enables content generators, like medical writers, and other content generators across several industries, to seamlessly integrate LINK AI’s advanced large language model (LLM) functionality into the widely used MS Word application. This innovation significantly enhances the efficiency and quality of the document creation experience.

The new AI Assistant from TrialAssure was developed in response to direct industry feedback from medical writers who must work in MS Word, citing its comprehensive formatting and editing features. This update ensures that users no longer need to compromise on document quality or efficiency when using AI-powered content generating applications.

“Medical writers live and breathe Microsoft Word,” said Prasad M. Koppolu, COO, TrialAssure. “By integrating our LINK AI Assistant with the full functionality of MS Word, we’re providing writers with the best of both worlds to create complex, scientific documents faster, without sacrificing the rich functionality that they are accustomed to. At the same time, it allows companies to manage and deploy highly valuable writing subject matter experts across their portfolio in an optimal manner.”

Accelerating Document Creation in the Pharmaceutical Industry

The LINK AI medical writing tool is designed to help pharmaceutical companies meet growing resource demands and transparency compliance requirements across the drug development lifecycle. LINK® AI efficiently develops, translates, and drafts a wide range of clinical, technical, and plain language documents, such as:

Plain Language Summaries (PLS), PLS of clinical trial results, PLS of publications, PLS of Clinical Study Protocol, and Informed Consent Forms (ICF).
Clinical and technical documents, including Clinical Study Protocol, Clinical Study Report (CSR), patient safety narratives, and Statistical Analysis Plan (SAP) – built from industry standards and templates such as TransCelerate and CDISC.
Customizable templates, source types, and settings to produce any other document type.

“On average, LINK AI eliminates four weeks from a six-week drafting process, ensuring faster time-to-market and enhanced efficiency for medical writing teams.”

These drafts are created in a fraction of the time that it typically takes to write from scratch. On average, LINK AI eliminates four weeks from a six-week drafting process, ensuring faster time-to-market and enhanced efficiency for medical writing teams.

How LINK AI Works

TrialAssure LINK AI jumpstarts the writing process by digesting structured and unstructured data sources to instantly generate highly accurate document drafts based on standard or custom templates. Medical writers can refine and revise the content using intuitive prompts, modular editing tools, and AI-generated suggestions based on deep understanding of generative AI and best practices for prompt engineering.

Key features include:

Iterative Prompting: Refine AI-generated text effectively in an intuitive, chat-style format.
Text Validation: Utilize secondary AI agents to perform additional tasks, such as quality control, understandability assessment, style and formatting checks, and other customizable functions.
Integrated Graphics and Charts: Automatically generate visuals to complement text.

The LINK AI application also supports team collaboration by managing workflows, tracking internal approvals, and enabling remote teamwork—all designed to shorten timelines and reduce workload redundancies.

Early adopters have expressed enthusiasm for the AI assistant, citing its ability to streamline workflows and deliver professional-quality documents faster. “This enhancement allows us to combine AI innovation with the gold standard of document creation tools,” shared one Clinical Research Organization (CRO) partner.

To see how LINK AI can transform your medical writing process, watch the video and request a demo at https://www.trialassure.com/software/link/

ABOUT TRIALASSURE

TrialAssure® is an award-winning, global data transparency company with fast, affordable, and intelligent software and service solutions for the pharmaceutical industry and beyond. A leader in the use of artificial intelligence (AI) and machine learning (ML), TrialAssure built their AI Enabled, Human Driven™ software solutions to meet compliance goals through data, document, and image anonymization, development of technical and non-technical content using generative AI, compliance tracking, and more. Established in 2009, TrialAssure’s global team has a proven track record in building strong technology that adapts to ever-changing data transparency requirements and was named Data Solution of the Year in the Data Breakthrough Awards.

For more information, visit www.trialassure.com

BluXinga 2.0 Announces Major Upgrades to it Small Business HR Tool to Effectively Reduce Employee Burnout and Increase Retention Without the Complexity

Staff Writer

-

March 22, 2025

0

BluXinga 2.0 Announces Major Upgrades to it Small Business HR Tool to Effectively Reduce Employee Burnout and Increase Retention Without the Complexity

BluXinga, the emerging leader in human resource (HR) technology for professional services firms, announced the launch of BluXinga 2.0, a major upgrade to its platform designed to help small businesses increase morale, engagement, and employee retention. Now live, this launch represents a significant investment in user experience (UX) design and new features that focus on recognition, empowerment, and consistent real-time feedback to turn teams into higher performers.

BluXinga 2.0 introduces a sleek, modern interface that enhances usability while maintaining the platform’s lightweight, high-impact approach to HR management in small business environments.

Key features and benefits of BluXinga 2.0 includes the following:

Real-time recognition and feedback comes standard with an always-on feedback loop that helps employees better visualize success, pivot in the moment, and internalize a natural source of motivation.
Empower employees with public and private goal setting, to better track personal and professional goals within the app. Private goals remain visible only to the employee, encouraging self-motivation, individual growth, and a culture of empowerment.
Integrated coaching provides access to world-class goal-setting coaches and practical tools to strengthen both personal development and team performance to build healthier, more resilient teams.
Designed for small business success: Unlike complex enterprise HR systems that
overwhelm users with difficult workflows, BluXinga 2.0 keeps it simple to achieve easy
adoption and get teams up and running in a single afternoon.

“We have created the HR tool that my professional services firm needed, and today it gets a major upgrade,” said Kenneth Krys, CEO, BluXinga. “BluXinga 2.0 is an employee-driven app for employee-driven companies. In industries where your team’s skill, experience, and dedication make the difference, this upgrade doubles down on our commitment to helping small businesses create engaged, high-retention teams that drive real results.”

Why BluXinga 2.0 Matters for Small Businesses

Professional services firms—especially in accounting, finance, and legal sectors—often lack dedicated HR departments and need simple solutions that empower their employees and strengthen retention. BluXinga 2.0 bridges this gap by offering an affordable, lightweight platform that delivers everything small businesses need without the complexity of enterprise-level systems.

“Many business owners tell us that they want powerful HR tools but don’t have the bandwidth for bloated platforms, filled with loads of features that they’ll never use,” said Olivia Dannheiser, Director of People and Product Operations, BluXinga. “At less than the cost of corporate WiFi, BluXinga 2.0 delivers real gains in morale, engagement, and retention for small businesses without breaking the bank.”

Krys added, “One of the biggest advantages of partnering with BluXinga is that your voice matters. We take every piece of user feedback seriously and incorporate it directly into the platform.”

Coinciding with this launch, BluXinga is unveiling a brand-new website showcasing its platform and value proposition, and the company plans to release two new features in the months ahead. Getting started in BluXinga 2.0 is simple and easy, as most teams are fully set-up and operational the same day, with no heavy onboarding required. Experience the platform with a 14-day free trial at https://www.bluxinga.com/.

About BluXinga

Based in New York, BluXinga is an award-winning, next-generation HR tool designed to raise employee morale, increase retention rates, and lower the risk of burnout. Real-time feedback loops and recognition features help leaders create a positive work culture. Built specifically for small businesses, BluXinga offers a lightweight, easy-to-use solution tailored to accounting, legal, and finance firms without large HR departments. To experience the BluXinga difference, request a free trial at www.bluxinga.com.

SW North America’s BA 322i Twin-Spindle CNC Machining Center Showcases Smart Manufacturing for Medical, Aerospace, and Automotive Industries at Eastec 2025

Staff Writer

-

March 22, 2025

0

SW North America’s BA 322i Twin-Spindle CNC Machining Center Showcases Smart Manufacturing for Medical, Aerospace, and Automotive Industries at Eastec 2025

SW North America, a leading supplier of horizontal multi- and single-spindle CNC machining centers, automation, and complete system solutions, announced that its manufacturing automation capabilities will be on display at EASTEC by the Manufacturing Technology Series EAST at the Eastern States Exposition (1305 Memorial Ave., West Springfield, Mass.) on May 13-15, 2025.

At the event, SW North America will feature a live demonstration of its BA 322i, a compact, twin-spindle horizontal CNC machining center engineered to deliver fully autonomous, high-precision production for demanding industries, including aerospace, medical device manufacturing, and automotive. The BA 322i is designed as a complete manufacturing cell. With a Fanuc LRmate 200id 7L robot and onboard workpiece storage, the machine runs continuously with minimal human intervention—making it ideal for manufacturers looking to boost productivity while reducing labor costs and floor space requirements.

Key highlights of the live machining demonstration will include:

Autonomous, High-Precision Production: The BA 322i will machine Tibia Spacers, critical components used in total knee prosthetics, live in the exhibit hall at Eastec. The live demonstration will utilize ABS plastic, while production applications often use advanced materials like PEEK, known for its strength, biocompatibility, and bone-like density.
Fully-Automated Workflow: The system automates the entire process—from raw stock loading into the storage elevator, to OP10 and OP20 processing, and returning the finished parts to storage—without the need for manual handling. This lights-out machining capability allows for extended unmanned shifts.
Versatility for Large Industries: Built for precision, speed, and flexibility, the BA 322i is well-suited for machining complex aerospace components that require tight tolerances and high-quality finishes. Its automation features are equally beneficial for medical devices, automotive parts, agriculture and heavy trucking, and general industrial applications.

“The BA 322i is a prime example of how SW North America combines precision engineering with intelligent automation to meet the evolving needs of medical, aerospace, and automotive manufacturers,” said Mark Reichenbacher, President and CEO, SW North America. “At this year’s Eastec, attendees will see firsthand how this system reduces downtime, increases output, and maintains exceptional quality—all within a smaller manufacturing footprint.”

Visit SW North America at booth number 1318 at Eastec to explore the BA 322i and learn how SW’s machining centers and automation solutions can advance your production goals, or connect with us at https://sw-machines.com/us/.

About SW North America

SW North America is a subsidiary of Schwäbische Werkzeugmaschinen GmbH, a leading international manufacturer of smart manufacturing solutions. With its North American headquarters in Michigan, SW is the world market leader in multi-spindle CNC machining centers for cutting a variety of materials in the automotive, electromobility, agricultural and construction machinery, medical technology, and aerospace industries.

SW currently has more than 1,700 employees across its global headquarters in Schramberg-Waldmössingen, Germany, and locations in China, France, Hungary, Mexico, Poland, and the United States. The company achieved a group turnover of $535 million in 2022.

Learn more about SW North America at https://sw-machines.com/us/.

Contacts

Media Contact: Jennifer Brozek, Marketing Manager

Email: Jennifer.Brozek@sw-machines.com

Phone: 248-878-7862

Sales Contact: Andrew Rowley, General Sales Manager

Email: Andrew.Rowley@sw-machines.com

Phone: 330-298-8295

###

MMS REMS-Focused Technology Bolsters Full-Service REMS Solutions

Featured

Staff Writer

-

March 21, 2025

0

MMS REMS-Focused Technology Bolsters Full-Service REMS Solutions

CANTON, Mich. (March 19, 2025) – MMS, an award-winning, data-focused clinical research organization (CRO), is showcasing its expansion as a tech-enabled, full-service Risk Evaluation and Mitigation Strategies (REMS) solutions provider today during a presentation given by CEO Dr. Uma Sharma at the REMS Industry Consortium (RIC) Annual Meeting today in Arlington, Virginia.

The integration of proprietary REMS-focused technology applications, with longstanding expertise in regulatory affairs and a commitment to advancing patient safety, establishes MMS as a leading REMS provider in the space. This strategic expansion, along with the integration of proprietary REMS-focused technology applications, reinforces the longstanding expertise in regulatory affairs and commitment to advancing patient safety through innovative safety and risk management solutions.

“With our deep regulatory expertise and strong track record of success, MMS is uniquely positioned to help sponsors navigate the complexities of REMS with efficiency and confidence,” said Dr. Sharma. “This area needs regulatory and safety expertise to evaluate risks real-time, which MMS is uniquely positioned to accomplish with our proprietary technology and regulatory expertise to mitigate and even exit REMS. We do this while maintaining the highest level of compliance, patient safety, and prescriber habit re-enforcement at all times.

For nearly two decades, MMS has been a trusted partner in regulatory strategy, data science, and regulatory writing, helping life sciences companies achieve compliance and approval success. This latest tech-enabled real-time evaluation of safety with REMS solutions builds on that legacy, ensuring that sponsors have the following support:

End-to-end solutions that streamline the design, implementation, and ongoing management of REMS via our white-glove PMO capabilities
Regulatory and safety experts who partner with sponsors at the NDA/BLA submission stage to create tailored, data-driven REMS strategies for brands to ensure FDA compliance.
Advanced technology and real-time data visualization through Datacise® to empower sponsors in monitoring and optimizing REMS programs.
Simplified REMS processes by integrating comprehensive regulatory support with proactive issue resolution and strategic risk management insights.

“REMS compliance requires strategic planning, continuous monitoring, and expert regulatory guidance to ensure patient safety and program effectiveness,” said Christine Manley, REMS Director, MMS. “With our enhanced full-service REMS solutions, we are providing pharmaceutical and biotech sponsors with the right technology, expertise, and proactive support needed to effectively navigate FDA requirements and build sustainable, high-impact risk management programs.”

To mark this occasion, MMS has released a free eBook titled, The REMS Playbook: Strategies for Effective Risk Management in Drug Safety.

Download The REMS Playbook here
Learn more about MMS REMS solutions here

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com.

Cliniphai Creates AI-Powered Clinical Trial Localization and Translation Technology of the Future Designed for the Life Sciences Industry

Life Sciences

Staff Writer

-

March 21, 2025

0

Cliniphai Creates AI-Powered Clinical Trial Localization and Translation Technology of the Future Designed for the Life Sciences Industry

Named Athena, it combines multiple LLMs with human-in-the-loop control

Great Falls, Montana and Kyiv, Ukraine – Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announces the launch of Athena, an AI-driven clinical localization and translation workbench designed specifically for the life sciences, healthcare, and pharmaceutical industries. Unlike standard translation engines, Athena provides an adaptive, guided, and fully transparent process to provide high-quality, regulatory-compliant translations that enhance both speed and accuracy.

Built to meet the needs of eCOA providers, clinical trial site and recruitment organizations, and clinical research organizations (CROs), Athena serves as a best-in-class AI-powered workbench that combines multiple large language models (LLMs). Athena maintains human-in-the-loop control to ensure the highest translation quality in a guided, not automated experience.

“My partners and I set out to build a tool that we needed – that our industry needs – to truly solve the challenges of clinical translation and localization,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Athena is our answer. This is the only workbench of its kind that is designed to empower expert translators with AI-driven support, guided parsing, and full workflow automation. You can’t rely solely on machines in the life sciences industry, but with Athena, we are making it easier to achieve accuracy, consistency, and compliance at an unexpected pace.”

Key Differentiators That Set Athena Apart

Athena by Cliniphai combines AI-driven efficiency with human expertise, delivering a guided, adaptive, and compliance-focused translation experience tailored for life sciences. Key differentiators include the following:

Adaptive and Context-Aware Translations: Athena understands dialects, terminology, and context, and it gives users the ability to add instructions, choose available dialects, simplify language, and maintain consistency across large-scale projects.
Auto-Review: Athena automates the guidance and management process, maintaining tone, terminology, and compliance.
Accelerated Rescue Translations: Athena is designed to compress timelines and handle high-stakes, large-scale translation projects on tight turnarounds.
Best-in-Class Service: Built with clever integration of proprietary AI-enabled services on top of industry leading workflow management, Athena can operate with scale to ensure smooth project handling, customer support, and compliance.
Powered by Real-World Expertise: Cliniphai has built deep operational experience across clinical studies and is working with trusted partners that have spent decades ensuring linguistic accuracy in life sciences.
Seamless API Integration: Fully accessible via API, Cliniphai allowing life sciences companies to integrate Athena directly into their existing platforms, workflows, and regulatory processes.
On-Premise Deployment for Maximum Security: Athena can be installed directly within your organization’s infrastructure, allowing you to maintain complete control over data, eliminate external communication delays, and integrate seamlessly with your existing workflows and processes.

A new standard for translations

Cliniphai’s globally-located team speaks more than 10 languages in-house, bringing a global perspective to clinical and regulatory translation challenges. Additionally, the company’s 17-person development team is actively refining the software development lifecycle and using AI, combined with the proper scientific acumen, to exceed industry expectations.

“Poor translations have led to millions in lawsuits in our industry, and Cliniphai is committed to ensuring this never happens to its customers. No matter the translation or localization need, it shouldn’t be a slow, painful process. So far, the feedback from our testing group has been very positive,” added Vladimir Mats, PhD, CEO and Co-Founder, Cliniphai. “Our goal from day one was to redefine clinical translation and localization workflows for the pharmaceutical and biotech industry, and today it becomes a reality.”

Martin added, “The team explored multiple entry points as an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, and after various prototypes, we decided to build translation and localization first. This is simply the beginning, and Cliniphai’s future is very bright.”

Ask for a demonstration of Athena by Cliniphai at www.cliniphai.com.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences that accelerates innovation, streamlines operations, and enables smarter decision-making across the entire value chain. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization tool focused on delivering secure, compliant, and high-quality solutions for life sciences. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences—without compromising accuracy, security, or compliance. For more information, visit: https://www.cliniphai.com/.

JuliaHub Doubles Investment in Advanced Pharmaceutical Modeling Platform

Staff Writer

-

March 8, 2025

0

JuliaHub Doubles Investment in Advanced Pharmaceutical Modeling Platform

JuliaHub is doubling its investment in the pharmaceutical sector, leveraging JuliaHub’s new-and-improved CFR Part 11-compliant pharmaceutical platform. This latest release introduces advanced capabilities that further streamline workflows, improve compliance, and drive innovation across pharmacometrics, modeling, and analytics. With this update, JuliaHub continues to redefine efficiency and impact in pharmaceutical innovation, supporting organizations from preclinical research to regulatory submissions.

A Unified Solution for Pharma Workflows

JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics. Unlike fragmented systems, it ensures seamless transitions between stages, boosting efficiency and collaboration. JuliaHub’s capabilities are further strengthened by its strong partnership with Pumas-AI, a joint venture company with JuliaHub since 2019.

Deepak Vinchhi, Co-founder and COO of JuliaHub, emphasized the value of this partnership:

“Our collaboration with Pumas-AI brings an unparalleled advantage in pharmaceutical development. By integrating advanced pharmacometric modeling with JuliaHub’s scalable, high-performance platform, we empower teams to achieve faster, more reliable outcomes – accelerating the delivery of life-saving treatments to patients. This partnership reflects a shared vision: to advance drug development through innovative, scalable, and compliant solutions that drive efficiency, accuracy, and groundbreaking discoveries across every stage of the pharmaceutical lifecycle.”

JuliaHub Board Member and ex-CEO of Snowflake, Bob Muglia, highlighted the platform’s transformational capabilities:

“The JuliaHub platform provides a suite of tools and features for pharma customers to effortlessly carry out analyses at each stage of the drug development process – supporting pre-clinical, clinical, post-marketing as well as regulatory submissions. Features such as Time Capsule greatly reduce the effort to meet regulatory requirements, making it faster and easier to bring new products to market and leading to tremendous savings in time and money. We are heavily investing in JuliaHub to establish it as a best-in-class solution for the pharmaceutical industry.”

Vijay Ivaturi, CEO of Pumas-AI, talked about JuliaHub’s impact on pharmaceutical development:

“Pumas-AI has successfully developed and submitted 26 drugs to the FDA using JuliaHub’s powerful platform. The scalability, performance, and compliance capabilities of JuliaHub have played a pivotal role in ensuring seamless drug development and regulatory success. JuliaHub is setting a new standard for efficiency and innovation in the pharmaceutical industry.”

Seamless Interoperability and Compliance

JuliaHub seamlessly integrates with industry-standard tools such as Pumas, RStudio, SAS, Nonmem, Monolix, and Phoenix, ensuring pharmaceutical teams can adopt the platform without disrupting existing workflows. It fosters collaboration through shared workspaces, built-in version control, and granular access controls while maintaining full regulatory compliance. Features like Time Capsule support traceability by retaining job information for years, and detailed audit logs enhance transparency and adherence to FDA 21 CFR Part-11 regulations, making regulatory submissions faster and more efficient.

Redefining Drug Development

20 of the world’s largest pharmaceutical companies are using JuliaHub, revolutionizing drug development from research to regulatory submissions.

For more information, visit https://juliahub.com/industries/pharma or contact sales@juliahub.com.

About JuliaHub: JuliaHub, founded by the creators of Julia, is a fast and easy-to-use code-to-cloud platform that accelerates the development and deployment of Julia programs, including artificial intelligence (AI) and scientific machine learning (SciML). JuliaHub users include innovative companies in a range of industries including aviation, aerospace, pharmaceuticals, automotive, energy, manufacturing, and semiconductor design and manufacture.

About Julia: Julia is a high performance, open source programming language that powers computationally demanding applications in modeling and simulation, drug development, design of multi-physical systems, electronic design automation, big data analytics, scientific machine learning and artificial intelligence. Julia solves the two language problem by combining the ease of use of Python and R with the speed of C++. Julia provides parallel computing capabilities out of the box and unlimited scalability with minimal effort. Julia has been downloaded by users at more than 10,000 companies and is used at more than 1,500 universities. Julia co-creators are the winners of the prestigious James H. Wilkinson Prize for Numerical Software and the Sidney Fernbach Award.

About PumasAI: PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company includes the Pumas® suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. For additional information, visit www.pumas.ai.

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

Life Sciences

Staff Writer

-

February 13, 2025

0

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient drug development.

With a history of strong organic growth, the acquisition of Exploristics positions MMS to enhance its global footprint and capabilities in advanced clinical trial design, innovative statistics, and data science. Building on its excellent track record in regulatory and end-game submissions, this acquisition now solidifies MMS as the leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.

“We are proud to bring the Exploristics team into the #OneMMS family,” said Dr. Uma Sharma, CEO, MMS. “When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organizations that would complement our existing regulatory approach and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software. We found that in Exploristics, along with a like-minded culture.”

Chris Schoonmaker, Chief Operating Officer at MMS, added, “Exploristics joining MMS is an exceptional fit, and we look forward to delivering even greater value to our clients through optimized strategies that reduce the overall time and cost burden in drug development.”

Expanding Expertise and Global Reach in Europe

The acquisition of Exploristics by MMS aligns with the company’s focus on broadening its data-focused solutions to enhance the ability to simulate, analyze, and optimize studies, as well as reduce risk and drive efficiencies. By combining the two organizations’ strengths, MMS will now provide:

Advanced statistical design and data science capabilities across diverse therapeutic areas and study types.
Enhanced and real-time pivots for orphan, rare, and special disease populations with an unmet medical need.
Study simulation and development planning with the integration of KerusCloud into an existing award-winning technology suite that boasts a 3x increase in development program success rates and up to USD 20 million saved on a single study.
Expanded global presence, with increased scale in Europe and access to a highly skilled team of biostatisticians and data scientists.

“Joining MMS represents an exciting new chapter for Exploristics,” said Aiden Flynn, Founder and CEO of Exploristics, now Senior Vice President, Head of Strategic Statistical Consulting at MMS. “Our ethos has always centered on openness, honesty, professionalism, flexibility, and creativity—qualities that I’ve experienced at MMS since day one of our discussions. I am confident that our employees, partners, and clients will benefit from this partnership as we amplify our impact and expand our global reach.”

Ben Dudley, Chief Commercial Officer at MMS, added “Our presence in Europe has seen significant growth in recent years, and this acquisition adds to our vitality in the region. Our focus on data for better trial data execution, lower risk, stronger submissions, integration of Real-World Data (RWD) into clinical outputs and accelerated outcomes has never been stronger than it is today.”

Learn more about MMS at https://www.mmsholdings.com.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com

About Exploristics

Exploristics is a world-leading technology-enabled services company that transforms clinical development for life sciences organizations with unique proprietary software and biostatistics consultancy supporting the planning, design, and analysis of clinical studies.

About KerusCloud®

KerusCloud, an MMS technology, is a revolutionary simulation-guided study design tool that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development times, costs, and patient burden.

Flow Secures First Wholesale Insurance AI Agent to Pass RPLU Exams

Insurance

Staff Writer

-

February 7, 2025

0

Flow Secures First Wholesale Insurance AI Agent to Pass RPLU Exams

Flow Specialty, the wholesale 3.0 specialty commercial brokerage, is announcing the industry’s first AI insurance broker. The brokerage’s Platformless AI model has passed RPLU certification exams for the Cyber, Errors & Omissions, and Executive liability modules. By attaining this level of rigor, Flow’s expert brokers have real leverage: AI agents who can take meaningful work off brokers’ plates. This milestone celebrates the ability to scale access to expertise — a capability that completely changes the specialty commercial insurance market dynamics.

Historically, the small and medium business segments across all industries have struggled to find comprehensive coverage that enables them to transfer risk confidently. This is because crafting commercial policies demands the expertise and time of brokers. However, brokers, who are there to deliver expertise on tailoring individual policies based on unique business needs, are only compensated for quotes that bind (about one in four quotes). This compensation structure means traditional brokers focus on large enterprises that yield lucrative commission dollars. Meanwhile, small and medium businesses are left exposed.

“For far too long, the middle market segment of specialty business has been underserved for retail brokers. I have been in this industry for more than two decades and have observed an underperformance around the quality of service, attention to details, and ability to serve the client in a manner they deserve. The stumbling blocks for wholesalers have been thin margins, bandwidth issues, and inconsistency of expertise across teams. We have solved these problems by using AI to dramatically scale our human brokers abilities far beyond what has been previously possible,” shares David Derigiotis, President of Brokerage and Head of Insurance.

Flow is building an ecosystem of AI agents who operate like the world’s best assistants. Based on the GPT 4.0 Omni core, Flow’s AI agents are trained on an ever-growing library of insurance materials—specimens, quotes, and carrier risk appetites—and the ongoing transaction of endless communication materials and critical decision points. Flow’s AI agents know not only materials but also understand tradeoffs and considerations.

Flow’s hybrid approach to human brokers supported by AI agents goes beyond mere data problem-solving. By digitizing knowledge, Flow’s internal workflow engine enables AI models to cross-reference materials, learn from broker interactions, and evolve continuously. These AI Agents are integral team members, handling labor-intensive tasks such as risk appetite matching, generating quote comparisons, and constructing review materials. Flow brokers are always in the loop, revising and overseeing the output of this workflow engine. This approach of experts supported by AI agents reduces the manual investment required by individual brokers and makes it possible to deliver an expert-rich experience for every premium.

“In an industry that runs on trust and relationships, like the commercial insurance space, scale is a real issue. How do you enable brokers to take on more workload without burning the bridges of trust? The key is to enable wholesale brokers with ultimate availability, every single time. And in order for our brokers to provide this level of service, we’re training our AI to operate as the world’s best assistant,” said CEO and Founder, Sivan Iram.

Learn more at www.flowspecialty.com.

Renowned Business Leader Klaus Kleinfeld Unveils New Book “Leading to Thrive”

Staff Writer

-

January 17, 2025

0

Renowned Business Leader Klaus Kleinfeld Unveils New Book “Leading to Thrive”

Klaus Kleinfeld, renowned business leader and former CEO of Siemens and Alcoa, today announced the release of his highly anticipated book, “Leading to Thrive: Mastering Strategies for Sustainable Success in Business and Life.” Success in both your business and personal lives is possible. You don’t have to choose one over the other. Leading to Thrive shows you how.

Klaus Kleinfeld draws on decades of global business experience from large scale to startups across a wide range of industries. He reveals how to win both the Outer Game of business success and the Inner Game of personal fulfillment.

Leading to Thrive charts a transformative path for building an inspiring vision, creating competitive advantages, and motivating world-class teams. Then, it goes deeper, exploring how to preserve and recover your energy, achieve balance, and find true purpose and meaning.

Filled with real-world advice from one of the world’s most experienced business practitioners, Leading to Thrive is a must-read for every business leader aiming for sustained success in business and in life.

“Success in business requires more than just hard work; it demands a holistic approach that integrates both personal well-being and organizational performance,” said Kleinfeld. “With this new book, I want to provide a roadmap for the leaders of today and tomorrow to help in navigating their journeys with both purpose and balance.”

Understanding the inner game versus the outer game

The Inner Game emphasizes the importance of effectively managing physical, emotional, mental, and spiritual energy as foundational elements for sustainable success in both business and life. It focuses on unlocking one’s inner strengths, creating resilience, and finding purpose.

Understanding these fundamentals enable leaders to enhance their performance, maintain balance, and navigate the challenges of today’s fast-paced environment. It allows them to fuel long-term growth and fulfillment.

The increased inner strength unlocks success in whichever Outer Game a leader chooses to engage. Within the text, Kleinfeld emphasizes common challenges like defining a winning strategy, flawlessly executing, high-performance team dynamics, and effective board and stakeholder management. Leaders are guided on how to create inspiring visions, build sustainable competitive advantages, and cultivate a collaborative culture that drives collective success.

By integrating insights from the Inner Game, leaders will learn how to constantly recharge – even in very little time – and refuel their Outer Game. Kleinfeld also touches upon optimizing one’s leadership style and making truly informed decisions that align with their values, ultimately resulting in impactful outcomes for their organizations and the communities they serve.

Early praise for Leading to Thrive

For this new release, Kleinfeld has garnered significant praise from some of the most influential leaders in business, including:

“Klaus Kleinfeld has had an amazing career leading some of the world’s great companies. In Leading to Thrive, he shares lessons he learned along the way with profound insights for lasting success in business and in life.” – Marc Benioff, Co-founder, Chairman, and CEO of Salesforce
“This book reflects Klaus’s commitment to helping leaders achieve success with purpose and balance.” -Jay Y. Lee, Executive Chairman of Samsung
“Klaus’s insights are both practical and inspiring—perfect for leaders at any stage.” – Stephen A. Schwarzman, Chairman, CEO and Co-founder of Blackstone
“Klaus is a visionary who understands big-picture and minute details. He has managed to master business and well-being…a rare quality.” – Diane von Fürstenberg, fashion designer and Founder of the DVF brand
“Klaus weaves together the principles of conscious leadership and sustainable success, offering a blueprint for aligning business with the deeper currents of life.” – Dr. Deepak Chopra, Founder of the Chopra Foundation and Chopra Global
“In addition to his incredible life story, Klaus gives his readers a roadmap to success in their own journeys. A must-read for anyone hoping to excel and go further than they thought.” – Ken Langone, entrepreneur, investor, and Co-founder of Home Depot

Leading to Thrive is available for purchase on Amazon, and learn more at: https://www.leading-to-thrive.com/

About Klaus Kleinfeld

Dr. Klaus Kleinfeld is the only leader to have successfully served as CEO of two Fortune 500 giants on different continents: Alcoa in the US and Siemens in Germany. With a nearly forty-year career spanning multiple industries, from established businesses to tech startups, he has advised US presidents and global leaders across Europe, Asia, and the Middle East. As the founder of K2Elevation, he invests in North American and European tech and biotech firms. Actively engaged in private sector, public affairs, and cultural boards, Dr. Kleinfeld, a dual US and European citizen, enjoys work, life, and family near New York.

Learn more: https://www.leading-to-thrive.com/

NewsWeekPRO

Boardroom Buzz

About MMS

Expanding Expertise and Global Reach in Europe

About MMS

About Exploristics

About KerusCloud®

Boardroom Buzz

About us

Company

The latest

Subscribe